Call(WhatsApp Us)
+8615360806100Email Us
cherry@laeyo.comSee the factory by live video walkthrough
Book an on-site factory visit in GuangzhouMost European baby care projects do not fail at the formula stage — they fail at the RFQ stage. A brief that says "mild shampoo for babies, EU market, 200 ml" leaves the manufacturer…
Most European baby care projects do not fail at the formula stage — they fail at the RFQ stage. A brief that says “mild shampoo for babies, EU market, 200 ml” leaves the manufacturer to assume the age band, the exposure scenario, the preservative strategy, the test panel and the pack format. Every one of those assumptions comes back later as a re-quote, a re-test, or a label that cannot be released. This checklist is built to be forwarded directly to a supplier so that the four decisions that carry the most cost and timeline — age group, testing, formula guardrails and packaging compatibility — are documented before a single sample is made.
Informational only, not legal advice. Confirm requirements with your EU Responsible Person and safety assessor.
The declared age band changes the exposure calculation in the CPSR (children have a higher surface-area-to-body-weight ratio), the acceptable preservative and fragrance load, the wording of label warnings, and often the pack format and fill size. Pick one primary band per SKU and do not let marketing widen it later without re-opening the file.
| Declared age band | What typically changes in the formula | What changes in testing | What changes in packaging |
|---|---|---|---|
| 0–3 months (newborn) | Shortest possible ingredient list; fragrance-free is the usual buyer guardrail; minimal preservation strategy justified by the safety assessor | Exposure scenario written for newborn use; irritation and eye-irritation data reviewed at higher scrutiny | Small fill, precise dosing, no splash risk, clear “keep out of reach of children” area on the label panel |
| 3–12 months | Mild surfactant systems, pH aligned to tears, low or no fragrance | Same core battery; panel must reflect sensitive-skin use, paediatric justification documented | One-hand pump or flip-top, wet-hand grip, drop-resistant |
| 12–36 months | Can accept mild fragrance with full allergen declaration; richer emollients for barrier products | Panel may include parents as users; consumer perception test becomes useful | Larger fill becomes viable; refill consideration starts here |
| 3–6 years | More “fun” sensorial allowed; still held to child-use exposure | Eye-irritation data matters more for shampoo (bathtime behaviour) | Tamper-evident closures, ergonomic grip for small hands if child-operated |
| 6–12 years | Approaches adult mildness positioning but claims wording stays child-directed | Standard adult-adjacent battery usually accepted | Formats can follow adult range architecture |
RFQ line to add: “Declared age band per SKU: ______. Confirm the exposure scenario used in the CPSR and the panel design that supports it.”
Ask for the documents, not the assurances. Each row below is a request you can paste into an email; the acceptance criteria stop the answer from being “we will provide later.”
| Document / test | Issued by | What it proves | Acceptance criteria |
|---|---|---|---|
| EU Responsible Person appointment | Brand / importer, with named EU entity | Legal basis for placing product on the EU market | Signed mandate with name, EU address and contact before CPNP filing |
| CPSR + PIF | Qualified safety assessor | Product is safe for the declared age band and use | Signed CPSR referencing this exact formula and pack; PIF index complete |
| CPNP notification | Responsible Person | Product notified before market placement | CPNP reference number issued for this formulation |
| GMP certificate | Manufacturing site | Production under ISO 22716 | Valid certificate naming the actual production site, not the trading office |
| Challenge test (ISO 11930) + micro limits (ISO 17516) | Accredited lab | Preservative system holds under the declared use | Report on the final formula in the final pack, passing criteria met |
| Stability + packaging compatibility | Manufacturer / lab | Product remains compliant and functional in the pack over shelf life | Accelerated plus real-time protocol, in-pack samples, pH/viscosity/micro/organoleptic checkpoints |
| Fragrance documentation: IFRA certificate (current amendment) + allergen declaration | Fragrance house | Fragrance is safe and correctly declared for the actual use | IFRA category stated for the real use (rinse-off vs leave-on), allergens listed with percentages |
| Article 19 label pack | Brand + RP review | Label is complete in the language(s) of the selling member state(s) | Approved artwork with INCI, nominal content, batch/PAO, warnings, RP name and address |
| Claim substantiation file | Brand + lab | Each claim is supported, not implied | Claim-to-evidence mapping table signed off before artwork lock |
Two points buyers regularly miss: fragrance allergen labelling under Regulation (EU) 2023/1545 runs with transition periods, so ask your RP for the applicable date for your SKU rather than assuming; and IFRA documentation is not a product approval — it supports one input and does not replace the CPSR.
Practical constraint: infant panels are rare for ethical and practical reasons. Expect the dossier to rest on adult sensitive-skin panels plus a documented paediatric-use justification, unless you are commissioning an ethics-approved paediatric study — which adds months, not weeks.
| Phase | Fastest safe path | Standard path | Evidence output |
|---|---|---|---|
| Brief and age-band lock | 1 week | 2 weeks | Signed brief with age band, claims list, pack direction |
| Formula selection | Platform formula, 1–2 weeks | New development, 4–6 weeks | Formula spec sheet, INCI, allergen calculation |
| Packaging lock | Stock pack, 1–2 weeks | Custom tool, 6–10 weeks | Pack spec, compatibility protocol, decoration proofs |
| Lab batch and stability start | 1 week | 2 weeks | Batch record, stability protocol with in-pack samples |
| Challenge and micro testing | 4–6 weeks (cannot compress) | 4–6 weeks | ISO 11930 and ISO 17516 reports |
| Stability read-out | Accelerated, 12 weeks, run in parallel | Accelerated plus real-time data before launch | Data tables, conclusion on shelf life and PAO |
| Label and claims review | 2 weeks, running parallel to stability | 3 weeks including RP review | Approved multilingual artwork, claim-to-evidence map |
| CPSR and PIF | 2–3 weeks after data package closes | 3–4 weeks | Signed CPSR, complete PIF |
| CPNP notification | 1 week | 1–2 weeks | CPNP reference number |
| Pilot and first production | 3–4 weeks | 4–6 weeks | Pilot report, batch COA, retained samples |
Compression comes from parallelising and from using a proven platform formula in a stock pack. It does not come from shortening challenge testing or launching without stability data — those are the two delays that become recall costs.
Symptom: the first production samples dispense too much or too little, or dose drifts across the run.
Root cause: pump specified against water rather than the actual viscosity and density; no dose testing on the real formula.
Prevention: dose-accuracy testing on filled units at start, middle and end of the run.
What to request from factory (evidence): dose measurement report (ml per stroke, tolerance) on the final formula in the final pack.
Symptom: edges curl or ink smears within weeks of consumer use.
Root cause: adhesive chosen for dry-room conditions; wrong surface-energy match to the resin; incompatible decoration method.
Prevention: humidity and wet-hand adhesion testing on decorated units before artwork lock.
What to request from factory (evidence): label adhesion and rub-resistance test report on the commercial substrate, plus the packaging supplier’s material declaration.
Symptom: scent fades or turns in the bottle; product near the shoulder smells different from product near the base.
Root cause: fragrance components absorbing into the resin or interacting with a plasticiser; no in-pack organoleptic stability.
Prevention: in-pack stability with sensory panel checks at each checkpoint, not just pH and viscosity.
What to request from factory (evidence): stability report including organoleptic evaluation at each interval, with the pack material named.
Symptom: retailer or marketplace asks for CPSR, COA or the allergen declaration and the file is missing or refers to a different formula version.
Root cause: documents produced at sampling stage and never updated to the commercial formula and pack; no document control.
Prevention: a single document register with version numbers tied to the launched formula code.
What to request from factory (evidence): document register listing CPSR, PIF index, COA, SDS, stability, micro, IFRA and allergen documents, each referencing the final formula code.
Symptom: label lists ingredients in the wrong order or omits a raw material present in production.
Root cause: artwork frozen before the formula was finalised; no reconciliation step.
Prevention: a formal artwork-to-formula reconciliation signed by the manufacturer before printing.
What to request from factory (evidence): signed reconciliation sheet comparing the printed INCI to the batch formula, per SKU.
Symptom: “tear-free”, “hypoallergenic” or a percentage claim cannot be defended when challenged.
Root cause: claims written by marketing after the test plan was fixed; unclear definitions.
Prevention: claim-to-evidence mapping completed before artwork, with each claim defined in writing.
What to request from factory (evidence): claim substantiation table linking each on-pack claim to a specific report, plus the definition used.
Symptom: mandatory information becomes unreadable at final print size, or warnings are dropped to make room.
Root cause: pack chosen before the language set was confirmed.
Prevention: test the full language set at final font size on the actual label area, including the thumbnail view for e-commerce.
What to request from factory (evidence): artwork proof at 1:1 scale with the complete mandatory text, plus RP sign-off.
Symptom: challenge test passed at lab scale but finished batches show out-of-spec micro results.
Root cause: process water quality, filling hygiene or a raw material supplier change after testing.
Prevention: change control on raw materials and environmental monitoring at filling.
What to request from factory (evidence): batch COA with micro results, environmental monitoring records, and written change-control procedure.
Share: declared age band per SKU and the intended use scenario.
Share: target member states and the required label language set.
Confirm: EU Responsible Person name, EU address and mandate status.
Confirm: whether a CPSR and full PIF will be delivered for this exact formula.
Provide: packaging direction (stock or custom), fill volume and closure type.
Provide: claim list with proposed on-pack wording for each claim.
Attach: fragrance brief or confirmation that the product is fragrance-free.
Confirm: preservation philosophy and whether a preservative-free claim is intended.
Lock: pH window, surfactant class restriction and viscosity target as numbers.
Lock: shelf life and PAO targets before stability starts.
Test: challenge test to ISO 11930 on the final formula in the final pack.
Test: micro quality to ISO 17516 with per-batch COA.
Test: in vitro skin irritation (OECD TG 439) and eye irritation (OECD TG 492) if claims require.
Test: sensitisation data (OECD TG 442C/D/E) supporting hypoallergenic positioning.
Test: stability including in-pack packaging compatibility with organoleptic checks.
Test: dose accuracy, drop and transport testing on filled units.
Test: label adhesion and rub resistance under humidity and wet-hand use.
Provide: IFRA certificate at the current amendment, matched to rinse-off or leave-on use.
Provide: fragrance allergen declaration with percentages against the regulatory thresholds.
Review: artwork at 1:1 scale with complete mandatory text in every language.
Approve: claim-to-evidence mapping table before artwork lock.
Approve: artwork-to-formula reconciliation signed by the manufacturer.
Confirm: no animal testing on finished product or ingredients for cosmetic purposes.
Provide: document register with version numbers tied to the launched formula code.
Confirm: raw material change-control procedure and notification commitment.
Confirm: pilot run date, first production lead time and MOQ per SKU.
No. It is a cosmetic under Regulation (EC) No 1223/2009 like any other. What changes is scrutiny: the safety assessment must reflect child exposure for the declared age band, and claims directed at babies attract closer attention from authorities and retailers. Plan for a stricter file, not a different file.
Not defensibly. “Tear-free” has no legal definition in the EU, so it is a claim you must substantiate. Build an OECD-referenced in vitro eye irritation dataset plus pH data, and write down exactly what the claim means for your SKU before the artwork is approved.
Typical standard path is 16–24 weeks from brief to first production, dominated by challenge testing (4–6 weeks) and accelerated stability (about 12 weeks). A proven platform formula in a stock pack can bring this to roughly 10–13 weeks by parallelising, but the test read-outs themselves cannot be shortened.
Yes. A refill pouch has a different surface-to-volume ratio, a different closure and different headspace behaviour. Treat it as a separate pack for compatibility and stability, and keep the refill fitment verified against the parent bottle.
An RFQ that omits the age band or the language set. Both change the formulation envelope, the panel design and the label area, so the manufacturer prices a guess and revises when the real requirement appears.
Send your age band, member states, pack direction and target launch date together — those four inputs let a manufacturer quote realistically instead of quoting a placeholder. If you want the RFQ reviewed against EU documentation requirements before you commit to a sample round, Request a Quote and include your SKU list, formats, positioning and timeline target for a faster response.